rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma.
|
31732945 |
2020 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our study suggested the intratumoral heterogeneity of EGFR-activating mutations in lung adenocarcinoma confirmed on the single-cell level, which might be associated with EGFR-TKIs response in lung adenocarcinoma patients harboring the EGFR L858R mutation.
|
31014278 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues.
|
31647198 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic information was analyzed and EGFR mutation results were performed in initial biopsy samples.Seven patients showed transformation from ADC to SCLC, of which 6 patients were 19 del EGFR mutation, only 1 patient is L858R mutations.
|
30896637 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>EGFR</i> exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarcinoma.
|
31064887 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 55-year-old female with EGFR mutation (L858R) was diagnosed with lung adenocarcinoma, who was responsive to first-generation EGFR-tyrosine kinase inhibitor (TKI).
|
31382924 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with advanced lung adenocarcinoma with membranous mutant EGFR (19del or 21 L858R) showed significantly longer progression-free survival than those with cytoplasmic mutant EGFR after gefitinib treatment.
|
31228625 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present study, we report cases of two synchronous lung adenocarcinomas composed of two distinct pathological subtypes with different EGFR gene mutations: a homozygous deletion in exon 19 of the papillary adenocarcinoma subtype and a point mutation of L858R in exon 21 of the tubular adenocarcinoma.
|
29090842 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All six L858R-mutant cavitary ADC patients had thick-wall cavity while thick-wall cavity was only identified in one thirds (3/9) of patients with 19DEL.
|
30352571 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All patients were diagnosed with advanced lung adenocarcinoma and harbored EGFR 19del or L858R mutations before treatment.
|
30196239 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with the early stage lung adenocarcinoma harboring either 19del or L858R share similar RFS and OS.
|
29026990 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Radical resection was performed and confirmed an EGFR exon 21 L858R lung adenocarcinoma.
|
29461911 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Compare the complete (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS) in Hispanic patients with lung adenocarcinoma treated with erlotinib with EGFR mutations (L858R or exon 19 deletion [Del19]) with and without concomitant EGFRamp.
|
30284706 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three patients with recurrent postoperative EGFR-mutant lung adenocarcinoma (exon 19 deletion in 16, L858R in 15, G719C in 2 patients) treated with gefitinib were studied.
|
29767258 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study describes the case of a 48-year-old man who was diagnosed with lung adenocarcinoma with an epidermal growth factor receptor (EGFR) 21 L858R mutation.
|
29552210 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
E19del and L858R, which are representative subtypes of mEGFR(+) lung adenocarcinoma, differ in terms of mutational spectrum, as the E19del-subgroup has a lower mutation burden and a higher Ti/Tv ratio than the SNV-subgroup.
|
30522449 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The left and right lower lobe lung adenocarcinomas contained EGFR gene mutations: an L858R point mutation in exon 21 in the left lesion and a deletion mutation in exon 19 in the right lesion.
|
30453894 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
|
29887244 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
|
29222872 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this study was to compare the efficacy and toxicity of gefitinib as first-line therapy and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 (L858R) or exon 19 deletion of <i>EGFR</i> mutation.
|
28721096 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Positive EGFR mutation status is a favorable prognostic factor in patients with surgically resected lung adenocarcinomas; however, EGFR mutation subtype (exon 21 L858R mutation or exon 19 deletion) exhibits no prognostic impact.
|
28826599 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we describe a 54-year-old Chinese man diagnosed with lung adenocarcinoma (cT4N3M1b, stage IV) with neuroendocrine differentiation and L858R mutation on exon 21.
|
28538405 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival.
|
28745320 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-five LADC patients who received epidermal growth factor receptor (EGFR)-TKI therapy, including ten who received tumor rebiopsy after development of resistance, were subjected to picoliter-ddPCR-cfDNA analysis to determine the fraction of cfDNA with TKI-sensitive (L858R and inflame exon 19 deletions) and -resistant (i.e., T790M) mutations, as well as their concordance with mutation status in rebiopsied tumor tissues.
|
26768482 |
2016 |